News
The program emphasized the importance of incorporating patient and caregiver perspectives alongside clinical expertise to support personalized, empathetic care and shared decision-making in managing ...
The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...
New criteria make high-risk smoldering multiple myeloma treatable, opening door to future 'chronic' disease status ...
This case report retrospectively evaluated the diagnosis and treatment of a multiple myeloma (MM) patient with early relapse in the central nervous system (CNS) post autologous hematopoietic stem cell ...
Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for relapsed/refractory multiple myeloma.
A brain abscess is a localized collection of pus in the brain, often resulting from infections in nearby areas like the sinuses or ears. The classic triad of symptoms—fever, headache, and focal ...
The long-term benefits of CAR T-cell therapy, the use of residual disease activity to direct treatment, and a novel drug delivery system are among the multiple myeloma advances presented at ASCO 2025.
The 2025 Rocket Classic is all set to tee off this week at Detroit Golf Club, bringing PGA Tour excitement back to the Motor City.
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma The following represents disclosure information provided by ...
Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.
The median BMI of participants at risk for multiple myeloma decreased by nearly 7% after 12 weeks of a high-fiber diet. The intervention also improved quality of life and several metabolic markers.
A new standard of care Newly diagnosed multiple myeloma patients at Sylvester and other cancer centers are already routinely receiving the four-drug DKRd combination.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results